Novartis Message Board - Msg: 13773176

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 123.84

+1.0%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark H. Bornfeld who wrote ()	5/24/2000 11:10:00 PM
From: Jack Hartmann	of 296

Novartis Irritable Bowel Syndrome Pdt Effective In Study Dow Jones Newswires SAN DIEGO -- A recent study showed Novartis AG's (NVS) Zelmac drug relieved key symptoms in patients with irritable bowel syndrome. In a press release Wednesday, the company said the 12-week study of 881 patients reported a higher percentage of patients treated with Zelmac experienced a relief of symptoms - which include abdominal pain, overall well-being and altered bowel function - compared with patients given a placebo. The research was announced with related studies at the combined annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy and Society for the Surgery of the Alimentary Tract. Zelmac also was found to be well tolerated with most side effects comparable with placebo. In addition, another human study reported at the meeting showed the drug accelerated gastrointestinal transit following both oral and intravenous therapy. A new drug application for Zelmac was submitted for Zelmac to the Food and Drug Administration on Feb. 11, for treating irritable bowel syndrome and was granted priority review. Novartis also is assessing Zelmac as a potential treatment of other gastrointestinal disorders, such as gastroesophageal reflux disease and functional dyspepsia. -Michael Goodman; Dow Jones Newswires; 201-938-5400 ****************** Interesting article. I didn't know there was such a problem. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next